Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHID-PLUS: Capecitabine vs Paclitaxel with Trastuzumab in HER2+ Early Breast Cancer
NCT06992882Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Jul 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06992882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992882.